Canada Life’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.19M | Sell |
15,977
-773
| -5% | -$153K | 0.01% | 959 |
|
|
2025
Q4 | $3.16M | Sell |
16,750
-6,549
| -28% | -$1.26M | 0.01% | 952 |
|
|
2025
Q3 | $4.03M | Buy |
23,299
+335
| +1% | +$49.8K | 0.01% | 913 |
|
|
2025
Q2 | $2.61M | Buy |
22,964
+781
| +4% | +$83.5K | ﹤0.01% | 1084 |
|
|
2025
Q1 | $2.33M | Sell |
22,183
-1,997
| -8% | -$226K | ﹤0.01% | 1137 |
|
|
2024
Q4 | $2.58M | Buy |
24,180
+482
| +2% | +$54.5K | ﹤0.01% | 1150 |
|
|
2024
Q3 | $2.37M | Hold |
23,698
| – | – | ﹤0.01% | 1225 |
|
|
2024
Q2 | $1.99M | Buy |
23,698
+1,997
| +9% | +$159K | ﹤0.01% | 1284 |
|
|
2024
Q1 | $1.58M | Buy |
21,701
+1,037
| +5% | +$76.5K | ﹤0.01% | 1355 |
|
|
2023
Q4 | $1.47M | Buy |
20,664
+29
| +0.1% | +$1.71K | ﹤0.01% | 1376 |
|
|
2023
Q3 | $1.23M | Buy |
20,635
+553
| +3% | +$36.4K | ﹤0.01% | 1405 |
|
|
2023
Q2 | $1.45M | Buy |
20,082
+1,851
| +10% | +$139K | ﹤0.01% | 1351 |
|
|
2023
Q1 | $1.34M | Sell |
18,231
-1,393
| -7% | -$99K | ﹤0.01% | 1399 |
|
|
2022
Q4 | $1.31M | Sell |
19,624
-13,350
| -40% | -$868K | ﹤0.01% | 1421 |
|
|
2022
Q3 | $1.77M | Buy |
32,974
+6,294
| +24% | +$370K | 0.01% | 1232 |
|
|
2022
Q2 | $1.48M | Buy |
26,680
+3,619
| +16% | +$205K | ﹤0.01% | 1301 |
|
|
2022
Q1 | $1.66M | Sell |
23,061
-157
| -0.7% | -$11.4K | ﹤0.01% | 1297 |
|
|
2021
Q4 | $2.23M | Sell |
23,218
-144
| -0.6% | -$13.3K | ﹤0.01% | 1145 |
|
|
2021
Q3 | $2.04M | Buy |
23,362
+13,136
| +128% | +$1.02M | ﹤0.01% | 1171 |
|
|
2021
Q2 | $836K | Hold |
10,226
| – | – | ﹤0.01% | 1595 |
|
|
2021
Q1 | $971K | Sell |
10,226
-913
| -8% | -$86.3K | ﹤0.01% | 1536 |
|
|
2020
Q4 | $691K | Sell |
11,139
-1,151
| -9% | -$65.6K | ﹤0.01% | 1657 |
|
|
2020
Q3 | $729K | Sell |
12,290
-742
| -6% | -$50.6K | ﹤0.01% | 1543 |
|
|
2020
Q2 | $909K | Sell |
13,032
-576
| -4% | -$36.5K | ﹤0.01% | 1485 |
|
|
2020
Q1 | $615K | Sell |
13,608
-279
| -2% | -$15.8K | ﹤0.01% | 1521 |
|
|
2019
Q4 | $896K | Buy |
+13,887
| New | +$928K | ﹤0.01% | 1539 |
|
|
2019
Q3 | – | Sell |
-19,180
| Closed | -$1.36M | – | 1749 |
|
|
2019
Q2 | $1.36M | Sell |
19,180
-989
| -5% | -$72.8K | ﹤0.01% | 1374 |
|
|
2019
Q1 | $1.58M | Sell |
20,169
-370
| -2% | -$28K | ﹤0.01% | 1184 |
|
|
2018
Q4 | $1.61M | Sell |
20,539
-21,820
| -52% | -$2.33M | ﹤0.01% | 1138 |
|
|
2018
Q3 | $7.25M | Sell |
42,359
-1,278
| -3% | -$193K | 0.02% | 594 |
|
|
2018
Q2 | $5.64M | Sell |
43,637
-1,346
| -3% | -$150K | 0.01% | 676 |
|
|
2018
Q1 | $4.63M | Buy |
44,983
+392
| +0.9% | +$38.8K | 0.01% | 728 |
|
|
2017
Q4 | $3.81M | Sell |
44,591
-718
| -2% | -$62.2K | 0.01% | 804 |
|
|
2017
Q3 | $3.81M | Buy |
45,309
+960
| +2% | +$76K | 0.01% | 795 |
|
|
2017
Q2 | $3.36M | Buy |
44,349
+1,523
| +4% | +$107K | 0.01% | 839 |
|
|
2017
Q1 | $2.83M | Buy |
42,826
+2,480
| +6% | +$163K | 0.01% | 923 |
|
|
2016
Q4 | $2.56M | Sell |
40,346
-636
| -2% | -$40.1K | 0.01% | 949 |
|
|
2016
Q3 | $2.61M | Buy |
40,982
+1,349
| +3% | +$99.1K | 0.01% | 907 |
|
|
2016
Q2 | $2.95M | Buy |
39,633
+36,270
| +1,079% | +$2.69M | 0.01% | 830 |
|
|
2016
Q1 | $224K | Buy |
3,363
+1,197
| +55% | +$72.7K | ﹤0.01% | 1249 |
|
|
2015
Q4 | $147K | Hold |
2,166
| – | – | ﹤0.01% | 1480 |
|
|
2015
Q3 | $116K | Hold |
2,166
| – | – | ﹤0.01% | 1596 |
|
|
2015
Q2 | $136K | Hold |
2,166
| – | – | ﹤0.01% | 1634 |
|
|
2015
Q1 | $104K | Hold |
2,166
| – | – | ﹤0.01% | 1767 |
|
|
2014
Q4 | $72K | Hold |
2,166
| – | – | ﹤0.01% | 1945 |
|
|
2014
Q3 | $64K | Hold |
2,166
| – | – | ﹤0.01% | 1937 |
|
|
2014
Q2 | $84K | Hold |
2,166
| – | – | ﹤0.01% | 1695 |
|
|
2014
Q1 | $90K | Hold |
2,166
| – | – | ﹤0.01% | 1480 |
|
|
2013
Q4 | $72K | Buy |
+2,166
| New | +$70.6K | ﹤0.01% | 1570 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Canada Life's LGND Position: Q1 2026 in Review
Canada Life reduced its Ligand Pharmaceuticals (LGND) stake by 4.6% in Q1 2026, selling an estimated $153K and leaving 15,977 shares worth $3.19M. The position accounts for 0.01% of the portfolio, ranked #959.
Canada Life first reported a position in LGND in Q4 2013 and has held it in 49 quarters since. The position peaked at $7.25M in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Canada Life held 15,977 shares of Ligand Pharmaceuticals worth $3.19M as of Q1 2026.
- Canada Life sold 773 Ligand Pharmaceuticals shares in Q1 2026, an estimated $153K.
- Ligand Pharmaceuticals made up 0.01% of Canada Life's portfolio in Q1 2026, its #959 holding.
- Canada Life first reported a position in Ligand Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
- Canada Life's Ligand Pharmaceuticals position peaked at $7.25M in Q3 2018.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.